How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,637 results for

Factor IX Deficiency

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Acute Treatments for Migraine

Migraine Disability Assessment mITT Modified intention-to-treat MQoLQ Migraine Quality of Life Questionnaire LCD Local Coverage Determinations LY Life year n Number of participants N Total number of participants N/A Not applicable ©Institute for Clinical and Economic Review, 2020 Page ix Final Evidence Report- Acute Treatments for Migraine Return to Table of Contents NCD National Coverage Determinations NICE National Institute for Health and Care Excellence NMA Network meta-analysis NR Not reported n.s (...) work productivity, increased disability claims and account for $11-50 billion in total costs. 4-6,7,8,9 The precise cause of migraine is not known and there is no specific test to confirm the diagnosis. 10-12 Migraine often starts in early adulthood, is more common in women, runs in families, and attacks can be triggered by a variety of predisposing factors such as stress and certain stimuli, activities and foods. 2,3,13,14 Treatment broadly includes acute therapies to quickly abort episodic

2020 California Technology Assessment Forum

182. Treatment of Depression in Children and Adolescents

of suicidal ideation or behavior for other SSRIs for adolescents and children with MDD or other DD (7–18 years) (10 RCTs [n = 2,368]; relative risk, 1.14 [95% CI, 0.89 to 1.45]; I 2 , 8%). However, this report excluded data on inpatients and those without depressive disorders, whom the Food and Drug Administration included in finding an increased risk of suicidality for all antidepressants across all indications. ix Conclusions. Efficacious treatments exist for adolescents with MDD. SSRIs may

2020 Effective Health Care Program (AHRQ)

183. Evidence-Based Clinical Guidelines for Multidisciplinary Spine Care: Diagnosis and Treatment of Low Back Pain

literature which excluded conditions such as presence of a neurological deficit or leg pain experienced below the knee, among others. Given the exclusion criteria, these guideline rec- ommendations address a subset of low back pain care as opposed to low back pain in its entirety. This clinical guideline is not intended to be a fixed treatment protocol; it is anticipated that there will be patients who require more or less treatment than what is outlined. This clinical guideline should not be construed (...) Society (SIS) Contributors: Michael P. Dohm, MD Thomas J. Gilbert, MD Joseph Gjolaj, MD Matthew Smuck, MD, Stakeholder Representative, American Academy of Physical Medicine and Rehabilitation (AAPM&R)Diagnosis & Treatment of Low Back Pain | Preface Recommendations were developed based on a specific definition, inclusion/exclusion criteria, and the resulting literature which excluded conditions such as presence of a neurological deficit or leg pain experienced below the knee, among others. Given

2020 American Academy of Pain Medicine

184. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders

during labor and delivery. (15) In all patients, careful attention should be paid to fluid restriction, since excessive water intake can lead to hyponatremia and seizures. B. Treatment of Hemophilia B 1. Recombinant Factor IX Concentrate Recombinant factor IX (rFIX) is produced in CHO cells; no human or animal plasma-derived proteins are used in the manufacturing process or in the final formulation vial (third generation product). Thus, the risk of human blood-borne viral contamination is much lower (...) than for plasma-derived factor IX concentrates. (16) New third generation recombinant Factor IX products are fused with either the Fc fragment of human IgG (rFIXFc) or with albumin (rFIX-FP), both of which inhibit lysosomal degradation of rFIX by endothelial cells. One is conjugated with PEG (N9-GP) to reduce clearance, thus prolonging the half-life of rFIX in the circulation. rFIXFc is produced in a human embryonic kidney (HEK) cell line (32), while rFIX-FP and N9-GP are produced in CHO cells (36

2020 National Hemophilia Foundation

185. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations

(risk of deficiency and risk of iron overload)? ix Question 2. Is ferritin an adequate marker for assessing the impact of iron interventions? xi Question 3. How should ferritin be measured? xi Question 4. Should ferritin be measured in combination with indicator(s) xii of infection or inflammation? Question 5. What are the population prevalence ranges for determining xiii a public health problem? Research gaps xiv Plans for updating the guideline xiv INTRODUCTION 1 Objectives 2 Scope 2 Population (...) /9789241504225_eng.pdf?sequence=1&isAllowed=y).ix Available evidence The following key questions were posed, based on the policy and programme guidance needs of Member States and their partners. The population, indicator, comparator, outcomes (PICO) format was used, when appropriate. 1. Is ferritin an adequate marker of iron stores (risk of deficiency and risk of iron overload)? 2. Is ferritin an adequate marker for assessing the impact of iron interventions? 3. How should ferritin be measured? 4. Should ferritin

2020 World Health Organisation Guidelines

186. Noninvasive Nonpharmacological Treatment for Chronic Pain

the interventions of interest to biofeedback and evidence from comparisons with pharmacological interventions was insufficient. Key Question 6: Differential Efficacy Evidence was insufficient to determine whether factors such as age, sex, comorbidities or degree of nociplasticity/central sensitization modify the effects of treatment. Harms Although data on harms were limited, no evidence suggested serious harms (e.g., death, disability, or need for intensive medical attention) for the interventions included (...) exercise, 21 acupuncture, 22 and complementary health approaches 23 for chronic pain management, as well as a review of chronic pain treatment guidelines on the use of manual and physical therapies. 24 Applicability New trials included for this update did not provide additional clarity on applicability. The applicability of our findings continues to be impacted by a number of factors. Symptom duration, clinical characteristics, comorbid conditions, the presence of overlapping chronic pain conditions

2020 Effective Health Care Program (AHRQ)

187. AIM Cancer Treatment Pathways

factor vs classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001 May;19(10):2638-46. PMID: 11352955 8. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity MVAC chemotherapy and GCSF versus classic MVAC in advanced urothelial tract tumours. Eur J Cancer. 2006 Jan;42(1):50-54. PMID: 16330205 9. Lorusso V, Pollera CF, Antimi M, et al. A phase II (...) from the randomized phase III ExteNET trial. Ann Oncol. 2019;23:23. PMID: 30689703 38. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366- 73. PMID: 21768458 39. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J

2020 AIM Specialty Health

188. Interventions for Substance Use Disorders in Adolescents: A Systematic Review

Than Alcohol or Cannabis 37 Risk of Bias 38 Network Meta-Analyses 38 Systematic Reviews of Treatments for Alcohol Use in the College Setting 54 ix Key Points 54 General Population of College Students Who Drink Alcohol 55 College Students Mandated To Receive Interventions for Alcohol Use 56 College Students Who Engaged in Heavy or Hazardous Levels of Alcohol Use 56 Risk of Bias 57 Pharmaceutical Interventions 59 Key Points 59 Opioid Use Disorder 59 Alcohol Use Disorder 64 Cannabis Use 67 Comorbid

2020 Effective Health Care Program (AHRQ)

189. Assessment of taste disorders

of the trigeminal nerve (cranial nerve V). Surgical procedures involving the posterior mandible may damage the lingual nerve, causing a transient or permanent loss of taste. The posterior third of the tongue is innervated by the lingual branch of the glossopharyngeal nerve (cranial nerve IX) and the base of the tongue and epiglottis by the vagus nerve (cranial nerve X). From the cranial nerves, the fibres converge in the nucleus tractus solitarius (NTS) in the brainstem. Leaving the NTS, the taste fibres still (...) of taste. Saliva is the natural oral solvent that dissolves food components to reach the taste receptors. Taste is also influenced by salivary composition, as a specific quality must be above normal saliva concentration in order to be perceived. Epidermal growth factor and nerve growth factor in saliva in taste function may play a role. Thus, both saliva quantity and quality can influence gustatory sensation. Bardow A, Nyvad B, Nauntofte B. Relationships between medication intake, complaints of dry

2018 BMJ Best Practice

190. Haemophilia

Haemophilia Haemophilia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Haemophilia Last reviewed: February 2019 Last updated: March 2018 Summary A bleeding disorder, usually inherited, characterised by the deficiency of coagulation factor VIII or IX. Occurs almost exclusively in males due to an X-linked pattern of inheritance. Graded as mild, moderate, or severe, based on factor VIII or IX level. Musculoskeletal (...) bleeding is the most common type of haemorrhage. Treatment consists of coagulation factor VIII or IX replacement. A major complication of treatment is the development of inhibitory antibodies against infused factor VIII or IX. Definition Haemophilia is a bleeding disorder, usually inherited with an X-linked recessive inheritance pattern, which results from the deficiency of a coagulation factor. Haemophilia A results from the deficiency of clotting factor VIII. Haemophilia B results from the deficiency

2018 BMJ Best Practice

191. Management of stable angina

to a particular strength of recommendation. Other factors that are taken into account when forming recommendations include: relevance to the NHS in Scotland; applicability of published evidence to the target population; consistency of the body of evidence, and the balance of benefits and harms of the options. R For ‘strong’ recommendations on interventions that ‘should’ be used, the guideline development group is confident that, for the vast majority of people, the intervention (or interventions) will do more (...) is used to describe a clinical syndrome of predictable chest pain or pressure precipitated by activities such as exercise or emotional stress, which increase myocardial oxygen demand. Although classical stable angina can be predictable in onset, reproducible and relieved by rest or glyceryl trinitrate (GTN), other factors and circumstances can influence its development. Angina can be caused by various cardiovascular conditions but this guideline is restricted to the clinical situation where reduced

2018 SIGN

192. Nonacog beta pegol (haemophilia B) ? Benefit assessment according to §35a Social Code Book V

”). The dossier was sent to IQWiG on 27 October 2017. Research question The aim of the present report was to assess the added benefit of nonacog beta pegol in comparison with the appropriate comparator therapy (ACT) in the treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia B (congenital factor IX deficiency). For the benefit assessment, the research question presented in Table 2 resulted from the ACT specified by the G-BA. Table 2: Research question of the benefit assessment (...) of nonacog beta pegol Research question Therapeutic indication ACT a 1 Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia B (congenital factor IX deficiency) Recombinant or human plasma- derived coagulation factor IX products a: Presentation of the respective ACT specified by the G-BA. In cases where the company, because of the G-BA’s specification of the ACT, could choose a comparator therapy from several options, the respective choice of the company is printed in bold

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

193. Management of Cardiovascular Diseases during Pregnancy Full Text available with Trip Pro

Fertility treatment 3209 10.7 Recommendations 3209 11. Venous thrombo-embolic disease during pregnancy and the puerperium 3210 11.1 Epidemiology and maternal risk 3210 11.2 Risk factors for pregnancy-related venous thrombo-embolism and risk stratification 3210 11.3 Prevention of venous thrombo-embolism 3210 11.4 Management of acute venous thrombo-embolism 3210 11.4.1 Pulmonary embolism 3210 11.4.2 Acute deep vein thrombosis 3211 11.5 Recommendations 3211 11.5.1 Management of delivery 3211 12. Drugs (...) record a mean age between 28.8–31.2 years. The mild increase in maternal age does not justify an increase in CVD during pregnancy because of maternal age. However, pregnancies in the late reproductive years (or between ages of 40–50 years) are more frequently associated with an increasing prevalence of cardiovascular risk factors, especially diabetes, hypertension, and obesity. Additionally, an increasing number of women with congenital heart disease reach childbearing age. In western countries

2018 European Society of Cardiology

194. Public health guidance on active case finding of communicable diseases in prison settings

manifested active TB Public health guidance on active case finding of communicable diseases in prison settings SCIENTIFIC ADVICE vi Mandatory testing Testing which is offered to all eligible people and cannot be refused Opt-in testing Testing which is voluntary and offered to all eligible people, often on the basis of identified risk factors; the person chooses whether to have the test Opt-out testing Testing modality where all eligible people are informed that the test will be performed unless (...) in prison settings and for the general population, as the vast majority of people in prison eventually return to their communities. There are several risk factors associated with increased transmission rates in prison settings, e.g. proximity (aggravated by overcrowding), which is common in some EU/EEA correctional facilities; high-risk sexual behaviour; injecting drug use; sharing of injecting equipment; and tattooing and piercing [10,12]. Diet and individual hygiene are also important risk factors

2018 European Centre for Disease Prevention and Control - Public Health Guidance

195. ESC/ESH Management of Arterial Hypertension Full Text available with Trip Pro

Vascular endothelial growth factor WUCH White-coat uncontrolled hypertension 1 Preamble Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health (...) stiffening; consequently, SBP assumes even greater importance as a risk factor from midlife. In middle-aged and older people, increased pulse pressure (the difference between SBP and DBP values) has additional adverse prognostic significance. , 3.5 Hypertension and total cardiovascular risk assessment Hypertension rarely occurs in isolation, and often clusters with other CV risk factors such as dyslipidaemia and glucose intolerance. , This metabolic risk factor clustering has a multiplicative effect

2018 European Society of Cardiology

196. Commentary on the KDIGO Guideline on the Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD

of abnormal PTH levels in CKD-MBD Guideline 4.2.1 We suggest that CKD G3a-G5 patients with progressively rising or persistently elevated PTH levels should be evaluated for modifiable factors, which now includes high phosphate intake and vitamin D deficiency; treatment decisions should not be based on a single elevated value. Guideline 4.2.2 The updated guideline no longer recommends routine use of calcitriol or its analogs in non-dialysis CKD patients. We suggest that clinicians should reserve their use (...) (not graded) 2017 KDIGO Update 3.2.1: In patients with CKD G3a–G5D with evidence of CKD-MBD and/or risk factors for osteoporosis, we suggest BMD testing to assess fracture risk if results will impact treatment decisions (2B) Rationale It is now well established that patients with CKD G3a–G5D have increased fracture rates compared with the general population. In addition, it is clear that incident hip fractures are associated with substantial morbidity and mortality, again, greater than that seen in age

2018 Renal Association

197. Prevention and Control of Methecillin-Resistant Staphylcoccus Aureus (MRSA)

or infected with MRSA in residential care facilities 92 Appendix IX MRSA- Information for schools and day care facilities for children 95 Appendix X Matrix for work restrictions in colonised healthcare workers 99 Appendix XI MRSA surveillance definitions 100 Appendix XII MRSA- Related process indicators 102 Appendix XIII Areas for Further Research 103 Appendix XIV Ambulance transportation of patients colonised/infected with MRSA 105 Appendix XV Economic impact report 106 5.0 References 122 Tables Table 1 (...) : Elements of a programme to prevent and control MRSA to promote safe quality care 7 Table 2: Key Components of Standard Precautions 22 Table 3: Practical guidance on antibiotic choices for the management of moderate CA-MRSA SSTI 33 Table 4: Definition of contacts of CA-MRSA index cases 36 Table 5: Risk Factors for MRSA in HCWs 50 Table 6: Treatment - practical guidance for MRSA infections in adults 57 Table 7: Estimation of the costs of HCAI in Ireland for 2011 extrapolated from national

2019 National Clinical Guidelines (Ireland)

198. Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD

to severe ECOPD. Titrated oxygen reduces mortality. Future research is required to assess the effectiveness of several emerging nonpharmacologic and dietary treatments. ix Contents Evidence Summary ES-1 Introduction 1 Background 1 Key Questions 3 Methods 4 Literature Search Strategy 4 Search Strategy 4 Inclusion and Exclusion Criteria 5 Study Selection 7 Data Abstraction and Data Management 7 Assessment of the Risk of Bias of Individual Studies 7 Data Synthesis 7 Grading the Strength of Evidence (SOE (...) appears to be surprisingly scarce, given how relatively common the condition is. 16, 17 Goals of management of ECOPD include relieving symptoms and hastening the recovery from ECOPD by addressing precipitating factors (e.g. antibiotic treatment for infections), improving expiratory airflow and gas exchange (and thus improving breathing) by using inhaled bronchodilators, and reducing lung inflammation with corticosteroids. Nonpharmacologic treatments include supplemental oxygen, nutritional support

2019 Effective Health Care Program (AHRQ)

199. Management of Infants at Risk for Group B Streptococcal Disease

. However, human milk–associated GBS antibody is protective against GBS LOD, and it remains unclear whether human milk is simply a marker of heavy maternal and infant colonization or a source of infection. GBS Virulence Bacterial factors promote invasive GBS infection. Group B streptococci are characterized by immunologically distinct surface polysaccharide capsules that define 10 serotypes (types I, Ia, and II–IX). Worldwide, serotypes I–V account for 98% of carriage and 97% of infant invasive strains (...) streptococcal (GBS) disease in 1996. These guidelines were developed in collaboration with the American Academy of Pediatrics (AAP), the American College of Obstetricians and Gynecologists (ACOG), the American College of Nurse-Midwives, the American Academy of Family Physicians, and other stakeholder organizations on the basis of available evidence as well as expert opinion. The 1996 consensus guidelines recommended either an antenatal culture–based or risk factor–based approach for the administration

2019 American Academy of Pediatrics

200. What is the evidence on the methods, frameworks and indicators used to evaluate health literacy policies, programmes and interventions at the regional, national and organizational levels?

on the effect of an intervention on health literacy. The review found no evidence of the use of national or international datasets to evaluate policies, programmes or interventions, and no evidence on international, national or subnational health literacy evaluation frameworks. Studies were predominantly conducted in health service and education ix settings, and most measured health literacy at the personal/individual level using study-level data sources. Studies that assessed the effect of an intervention (...) , programmes and interventions to enable an in-depth understanding of health literacy capacity and the cultural and contextual factors that influence it; • increase the engagement of citizens, particularly vulnerable and marginalized communities and other relevant stakeholders, in participatory methods to develop measures of health literacy that are culturally and contextually relevant; • expand the evaluation of health literacy at the organizational and system levels, including on governance, coordination

2019 WHO Health Evidence Network

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>